- Home
- NMRA vs PBYI Comparison
NMRA vs PBYI Comparison
Compare NMRA & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRA
- PBYI
- Stock Information
- Founded
- NMRA 2019
- PBYI 2010
- Country
- NMRA United States
- PBYI United States
- Employees
- NMRA N/A
- PBYI N/A
- Industry
- NMRA
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- NMRA
- PBYI Health Care
- Exchange
- NMRA Nasdaq
- PBYI Nasdaq
- Market Cap
- NMRA 291.5M
- PBYI 263.4M
- IPO Year
- NMRA 2023
- PBYI N/A
- Fundamental
- Price
- NMRA $2.50
- PBYI $5.16
- Analyst Decision
- NMRA Buy
- PBYI Strong Buy
- Analyst Count
- NMRA 8
- PBYI 1
- Target Price
- NMRA $7.43
- PBYI $7.00
- AVG Volume (30 Days)
- NMRA 2.3M
- PBYI 434.6K
- Earning Date
- NMRA 11-06-2025
- PBYI 11-06-2025
- Dividend Yield
- NMRA N/A
- PBYI N/A
- EPS Growth
- NMRA N/A
- PBYI 434.29
- EPS
- NMRA N/A
- PBYI 0.97
- Revenue
- NMRA N/A
- PBYI $238,062,000.00
- Revenue This Year
- NMRA N/A
- PBYI N/A
- Revenue Next Year
- NMRA N/A
- PBYI N/A
- P/E Ratio
- NMRA N/A
- PBYI $5.40
- Revenue Growth
- NMRA N/A
- PBYI 8.63
- 52 Week Low
- NMRA $0.61
- PBYI $2.32
- 52 Week High
- NMRA $14.09
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- NMRA 68.71
- PBYI 54.97
- Support Level
- NMRA $1.68
- PBYI $5.20
- Resistance Level
- NMRA $2.72
- PBYI $5.61
- Average True Range (ATR)
- NMRA 0.20
- PBYI 0.24
- MACD
- NMRA 0.08
- PBYI -0.03
- Stochastic Oscillator
- NMRA 81.89
- PBYI 30.67
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.